Sergott Robert C

Sergott Robert C, Carelli Valerio, Newman Nancy J, Biousse Valérie, Yu-Wai-Man Patrick, Vignal-Clermont Catherine et al.

This study found that better baseline vision and thicker retinal nerve fiber and ganglion cell layers predict improved visual outcomes 1.5 years after gene therapy for LHON.

Yu-Wai-Man Patrick, Newman Nancy J, Biousse Valérie, Carelli Valerio, Moster Mark L, Vignal-Clermont Catherine et al.

Gene therapy for LHON (MT-ND4 variant) showed sustained bilateral visual improvement and good safety up to five years, offering promising long-term benefit for patients.

Newman Nancy J, Yu-Wai-Man Patrick, Carelli Valerio, Moster Mark L, Biousse Valerie, Vignal-Clermont Catherine et al.

This gene therapy study for early LHON found no significant visual acuity difference between treated and sham eyes, suggesting limited direct benefit from the injection itself.

Moster Stephen J, Moster Mark L, Scannell Bryan Molly, Sergott Robert C

This study found early retinal ganglion cell and inner plexiform layer thinning strongly correlates with vision loss in LHON, highlighting a critical therapeutic window within 6 months of diagnosis.

Sergott Robert C

This study developed an algorithm for early detection of vigabatrin-induced peripheral visual field loss, aiming to limit disabling vision impairment in treated epilepsy patients.

Piette Scott D, Sergott Robert C

This study highlights that optic disc cupping, often attributed to glaucoma, has many non-glaucomatous causes. Differentiating these is crucial to avoid misdiagnosis and ensure appropriate treatment for potentially ominous neuro-ophthalmic conditions.

Sergott Robert C

OCT accurately measures retinal nerve fiber layer and macular thickness in MS/optic neuritis, enabling assessment of axonal survival and neuroprotection in clinical trials.

Behbehani Raed S, Vacarezza Noel, Sergott Robert C, Bilyk Jurij R, Hochberg Fred, Savino Peter J

A 66-year-old's isolated optic nerve lymphoma was diagnosed via biopsy after other tests failed, highlighting biopsy's diagnostic value despite visual risks in complex cases.

Buono Lawrence M, Foroozan Rod, Sergott Robert C

Dominant optic atrophy, a common inherited optic neuropathy, causes slowly progressive central vision loss, specific visual field defects, and blue-yellow color vision issues, often with temporal optic disc pallor.

Foroozan Rod, Buono Lawrence M, Savino Peter J, Sergott Robert C

Scanning laser polarimetry in acute central retinal artery occlusion showed diffuse retinal nerve fiber layer thinning, indicating early, widespread nerve damage. This suggests SLP can identify acute RNFL loss in CRAO.

Foroozan Rod, Deramo Vincent A, Buono Lawrence M, Jayamanne D Gerard R, Sergott Robert C, Danesh-Meyer Helen et al.

This study found that while some GCA patients with vision loss (AION) had improved acuity after steroid treatment, their visual fields remained severely constricted, indicating a poor overall visual prognosis.

Maust Heather A, Foroozan Rod, Sergott Robert C, Niazi Sultan, Weibel Sandra, Savino Peter J

This study found methotrexate improved or stabilized vision and reduced steroid needs in three patients with sarcoid-associated optic neuropathy, suggesting it's a valuable treatment option, especially for steroid-intolerant patients.

Buono Lawrence M, Foroozan Rod, Sergott Robert C, Savino Peter J

NAION is an idiopathic ischemic optic nerve condition causing sudden, painless vision loss. Risk factors include disc morphology, age, and systemic diseases. Currently, no effective long-term treatment exists.

Buono Lawrence M, Foroozan Rod, Sergott Robert C, Savino Peter J

Genetic analysis suggests normal tension glaucoma (NTG) is linked to OPA1 gene variations, implying it might be a hereditary optic neuropathy rooted in mitochondrial dysfunction, challenging current diagnostic paradigms.

Foroozan Rod, Buono Lawrence M, Savino Peter J, Sergott Robert C

Research on acute optic neuritis found interferon beta-1a reduced multiple sclerosis risk by 50% in high-risk patients, guiding current treatment to prevent MS progression.